Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | EVP, Chief Scientific Officer | January 22, 2026 | January 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
VERTEX PHARMACEUTICALS INC / MA
Report date January 22, 2026 · Filed January 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 34,477 |
Ending reported balance
After 2026-01-22 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-01-22 · Grant · Acquired 7,866 · Balance 31,149 F1: Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest on 02/13/2026. Row 2 · 2026-01-22 · Grant · Acquired 3,328 · Balance 34,477 F2: Represents earned performance shares with respect to a performance stock unit award granted on 02/12/2025 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest in installments beginning on 02/24/2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest on 02/13/2026.
F2: Represents earned performance shares with respect to a performance stock unit award granted on 02/12/2025 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest in installments beginning on 02/24/2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 22, 2026 Filed Jan 26, 2026 21:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 3,328 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-26-000010 · wk-form4_1769461800.xml · nonDerivative · entry 2 ALTSHULER DAVID · CIK 0001550395 · EVP, Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,477 F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/12/2025 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest in installments beginning on 02/24/2026. Read SEC document |
| January 22, 2026 Filed Jan 26, 2026 21:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 7,866 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-26-000010 · wk-form4_1769461800.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · EVP, Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,149 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest on 02/13/2026. Read SEC document |
| May 15, 2025 Filed May 19, 2025 21:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 52 | $424.69 | $22,083.88 |
DisclosureSEC source: 0000875320-25-000201 · wk-form4_1747688856.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · EVP, Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,281 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1, which was entered into on 8/8/2024. Read SEC document |
| March 13, 2025 Filed Mar 17, 2025 20:09 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 3,231 | $510.00 | $1,647,810.00 |
DisclosureSEC source: 0000875320-25-000152 · wk-form4_1742242135.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · EVP, Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,281 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1, which was entered into on 8/8/2024. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 20:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 3,231 | $500.00 | $1,615,500.00 |
DisclosureSEC source: 0000875320-25-000144 · wk-form4_1741810093.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · EVP, Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,512 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1, which was entered into on 8/8/2024. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 3,231 | $490.00 | $1,583,190.00 |
DisclosureSEC source: 0000875320-25-000139 · wk-form4_1741208889.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · EVP, Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,743 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1, which was entered into on 8/8/2024. Read SEC document |
| February 27, 2025 Filed Feb 28, 2025 21:23 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,272 | $480.00 | $610,560.00 |
DisclosureSEC source: 0000875320-25-000120 · wk-form4_1740777806.xml · nonDerivative · entry 2 ALTSHULER DAVID · CIK 0001550395 · EVP, Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,974 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1, which was entered into on 8/8/2024. Read SEC document |
| February 26, 2025 Filed Feb 28, 2025 21:23 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 5,954 | $479.61 | $2,855,597.94 |
DisclosureSEC source: 0000875320-25-000120 · wk-form4_1740777806.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · EVP, Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,246 Read SEC document |
| February 25, 2025 Filed Feb 26, 2025 21:04 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 848 | $480.95 | $407,845.60 |
DisclosureSEC source: 0000875320-25-000101 · wk-form4_1740603887.xml · nonDerivative · entry 2 ALTSHULER DAVID · CIK 0001550395 · EVP, Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,200 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1, which was entered into on 8/8/2024. Read SEC document |
| February 24, 2025 Filed Feb 26, 2025 21:04 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 3,971 | $483.28 | $1,919,104.88 |
DisclosureSEC source: 0000875320-25-000101 · wk-form4_1740603887.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · EVP, Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,048 Read SEC document |
| February 20, 2025 Filed Feb 24, 2025 21:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,111 | $480.00 | $533,280.00 |
DisclosureSEC source: 0000875320-25-000099 · wk-form4_1740431255.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · EVP, Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,019 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1, which was entered into on 8/8/2024. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 21:19 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 2,293 | $463.46 | $1,062,713.78 |
DisclosureSEC source: 0000875320-25-000077 · wk-form4_1739999985.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · EVP, Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,130 Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 21:03 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 5,324 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-25-000055 · wk-form4_1739567001.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · EVP, Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,423 F1 · shares: Restricted stock unit award that vests in installments beginning on 02/24/2026. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 21:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 2,142 | $467.98 | $1,002,413.16 |
DisclosureSEC source: 0000875320-25-000031 · wk-form4_1739395266.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · EVP, Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,099 Read SEC document |
| February 04, 2025 Filed Feb 6, 2025 21:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 7,114 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-25-000005 · wk-form4_1738876056.xml · nonDerivative · entry 2 ALTSHULER DAVID · CIK 0001550395 · EVP, Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,241 F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/07/2024 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/04/2025 and the shares will vest in installments beginning on 02/17/2025. Read SEC document |
| February 04, 2025 Filed Feb 6, 2025 21:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 12,314 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-25-000005 · wk-form4_1738876056.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · EVP, Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,127 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2022 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/04/2025 and the shares will vest on 02/26/2025. Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 21:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 15 | $478.56 | $7,178.40 |
DisclosureSEC source: 0000875320-24-000229 · wk-form4_1732050530.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · EVP, Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,813 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1, which was entered into on 8/8/2024. Read SEC document |
| May 15, 2024 Filed May 17, 2024 20:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 54 | $430.93 | $23,270.22 |
DisclosureSEC source: 0000875320-24-000150 · wk-form4_1715977306.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · EVP, Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,813 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1, which was entered into on 5/10/2023. Read SEC document |
| February 26, 2024 Filed Feb 27, 2024 21:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 4,239 | $425.70 | $1,804,542.30 |
DisclosureSEC source: 0000875320-24-000095 · wk-form4_1709069025.xml · nonDerivative · entry 2 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,813 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1, which was entered into on 5/10/2023. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 21:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 3,970 | $431.79 | $1,714,206.30 |
DisclosureSEC source: 0000875320-24-000095 · wk-form4_1709069025.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,052 Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 21:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 3,002 | $421.77 | $1,266,153.54 |
DisclosureSEC source: 0000875320-24-000085 · wk-form4_1708722602.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,022 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1, which was entered into on 5/10/2023. Read SEC document |
| February 20, 2024 Filed Feb 21, 2024 21:13 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 4,002 | $420.79 | $1,684,001.58 |
DisclosureSEC source: 0000875320-24-000066 · wk-form4_1708549975.xml · nonDerivative · entry 3 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,024 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1, which was entered into on 5/10/2023. Read SEC document |
| February 20, 2024 Filed Feb 21, 2024 21:13 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 2,812 | $420.58 | $1,182,670.96 |
DisclosureSEC source: 0000875320-24-000066 · wk-form4_1708549975.xml · nonDerivative · entry 2 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,026 Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 21:13 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 3,750 | $424.01 | $1,590,037.50 |
DisclosureSEC source: 0000875320-24-000066 · wk-form4_1708549975.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,838 Read SEC document |
| February 12, 2024 Filed Feb 13, 2024 21:46 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 3,145 | $420.24 | $1,321,654.80 |
DisclosureSEC source: 0000875320-24-000039 · wk-form4_1707860733.xml · nonDerivative · entry 2 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,588 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1, which was entered into on 5/10/2023. Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 21:46 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 2,099 | $422.74 | $887,331.26 |
DisclosureSEC source: 0000875320-24-000039 · wk-form4_1707860733.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,733 Read SEC document |
| February 07, 2024 Filed Feb 8, 2024 21:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 7,114 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-24-000014 · wk-form4_1707426599.xml · nonDerivative · entry 3 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,832 F3 · shares: Restricted stock unit award that vests in installments beginning on 02/17/2025. Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 21:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 7,866 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-24-000014 · wk-form4_1707426599.xml · nonDerivative · entry 2 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,718 F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/06/2024 and the shares will vest in installments beginning on 02/10/2024. Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 21:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 5,814 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-24-000014 · wk-form4_1707426599.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,852 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/03/2021 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/06/2024 and the shares will vest on 02/20/2024. Read SEC document |
| November 15, 2023 Filed Nov 17, 2023 21:11 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 19 | $369.92 | $7,028.48 |
DisclosureSEC source: 0000875320-23-000039 · wk-form4_1700255434.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,038 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1, which was entered into on 5/10/2023. Read SEC document |
| August 09, 2023 Filed Aug 11, 2023 20:05 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 63 | $345.51 | $21,767.13 |
DisclosureSEC source: 0000899243-23-018044 · doc4.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,038 F1 · kind: Transaction made pursuant to Mr. Altshuler's company approved trading plan under Rule 10b5-1, which was entered into on 5/10/2023. Read SEC document |
| February 27, 2023 Filed Feb 28, 2023 21:40 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 302 | $289.60 | $87,459.20 |
DisclosureSEC source: 0001209191-23-013685 · doc4.xml · nonDerivative · entry 4 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,038 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $289.60 (range $289.49 to $289.65). Read SEC document |
| February 27, 2023 Filed Feb 28, 2023 21:40 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 300 | $288.74 | $86,622.00 |
DisclosureSEC source: 0001209191-23-013685 · doc4.xml · nonDerivative · entry 3 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,340 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $288.74 (range $288.42 to $289.37). Read SEC document |
| February 27, 2023 Filed Feb 28, 2023 21:40 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 3,636 | $287.23 | $1,044,368.28 |
DisclosureSEC source: 0001209191-23-013685 · doc4.xml · nonDerivative · entry 2 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,640 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $287.23 (range $286.80 to $287.72). Read SEC document |
| February 24, 2023 Filed Feb 28, 2023 21:40 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 3,970 | $289.12 | $1,147,806.40 |
DisclosureSEC source: 0001209191-23-013685 · doc4.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,276 Read SEC document |
| February 21, 2023 Filed Feb 22, 2023 21:25 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 900 | $294.73 | $265,257.00 |
DisclosureSEC source: 0001209191-23-011655 · doc4.xml · nonDerivative · entry 5 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,246 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $294.73 (range $294.47 to $295.37). Read SEC document |
| February 21, 2023 Filed Feb 22, 2023 21:25 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,843 | $294.03 | $541,897.29 |
DisclosureSEC source: 0001209191-23-011655 · doc4.xml · nonDerivative · entry 4 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,146 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $294.03 (range $293.45 to $294.42). Read SEC document |
| February 21, 2023 Filed Feb 22, 2023 21:25 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,223 | $292.76 | $358,045.48 |
DisclosureSEC source: 0001209191-23-011655 · doc4.xml · nonDerivative · entry 3 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,989 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $292.76 (range $292.25 to $293.12). Read SEC document |
| February 21, 2023 Filed Feb 22, 2023 21:25 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 36 | $291.01 | $10,476.36 |
DisclosureSEC source: 0001209191-23-011655 · doc4.xml · nonDerivative · entry 2 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,212 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. Read SEC document |
| February 17, 2023 Filed Feb 22, 2023 21:25 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 3,750 | $292.85 | $1,098,187.50 |
DisclosureSEC source: 0001209191-23-011655 · doc4.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,248 Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 21:11 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 308 | $301.02 | $92,714.16 |
DisclosureSEC source: 0001209191-23-010045 · doc4.xml · nonDerivative · entry 6 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,998 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F8 · price: Open market sales reported on this line occurred at a weighted average price of $301.02 (range $300.79 to $301.22). Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 21:11 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,888 | $300.11 | $566,607.68 |
DisclosureSEC source: 0001209191-23-010045 · doc4.xml · nonDerivative · entry 5 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,306 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $300.11 (range $299.76 to $300.70). Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 21:11 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,165 | $299.08 | $647,508.20 |
DisclosureSEC source: 0001209191-23-010045 · doc4.xml · nonDerivative · entry 4 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,194 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $299.08 (range $298.71 to $299.54). Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 21:11 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 395 | $297.97 | $117,698.15 |
DisclosureSEC source: 0001209191-23-010045 · doc4.xml · nonDerivative · entry 3 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,359 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $297.97 (range $297.50 to $298.35). Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 21:11 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 842 | $296.85 | $249,947.70 |
DisclosureSEC source: 0001209191-23-010045 · doc4.xml · nonDerivative · entry 2 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,754 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $296.85 (range $296.42 to $297.37). Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 21:11 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 800 | $295.79 | $236,632.00 |
DisclosureSEC source: 0001209191-23-010045 · doc4.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,596 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $295.79 (range $295.31 to $296.12). Read SEC document |
| February 13, 2023 Filed Feb 14, 2023 21:49 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 500 | $300.23 | $150,115.00 |
DisclosureSEC source: 0001209191-23-009174 · doc4.xml · nonDerivative · entry 6 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,396 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $300.23 (range $299.96 to $300.63). Read SEC document |
| February 13, 2023 Filed Feb 14, 2023 21:49 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,893 | $299.36 | $566,688.48 |
DisclosureSEC source: 0001209191-23-009174 · doc4.xml · nonDerivative · entry 5 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,896 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $299.36 (range $298.86 to $299.83). Read SEC document |
| February 13, 2023 Filed Feb 14, 2023 21:49 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,160 | $298.47 | $644,695.20 |
DisclosureSEC source: 0001209191-23-009174 · doc4.xml · nonDerivative · entry 4 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,789 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $298.47 (range $297.85 to $298.82). Read SEC document |
| February 13, 2023 Filed Feb 14, 2023 21:49 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 245 | $296.44 | $72,627.80 |
DisclosureSEC source: 0001209191-23-009174 · doc4.xml · nonDerivative · entry 3 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,949 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $296.44 (range $295.84 to $296.57). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.